This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Renal function has been shown to be a prognostic marker for cardiovascular events.1 We performed a databank-based analysis to investigate the prognostic value of renal function regarding functional outcome, recurrent stroke, and symptomatic intracranial hemorrhage (SICH) in stroke patients treated with IV recombinant tissue plasminogen activator (rtPA).
Methods.
All consecutive stroke patients (n = 196) treated with IV-rtPA (1998–2006) were included. IV-rtPA was used according to current guidelines.2 Baseline variables were extracted from our prospectively ascertained thrombolysis database.3 The ethics committee approved of our approach to ascertain and analyze data of all rtPA-treated stroke patients.
Estimates of renal function included serum-creatinine levels and glomerular filtration rates (GFR). Creatinine was measured at admission. GFR was calculated applying the simplified Modification of Diet in Renal Disease (MDRD) formula.4
Endpoints were good (modified Rankin scale [mRS] ≤2) vs poor outcome (mRS >2, including death [cause of immediate death based on information of treating physician]), recurrent ischemic stroke at 3 months (WHO criteria), and SICH (National Institute of Neurological Disorders and Stroke trial definition). All patients had CT or MR scan (72 hours) and additional scans in case of clinical deterioration.
Univariate analyses regarding good vs poor outcome were performed for creatinine, GFR, and baseline variables using Fisher exact tests or t tests. Secondly, multiple logistic regression was performed with the mRS >2 as dependent …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
White matter hyperintensity load on stroke recurrence and mortality at 1 year after ischemic stroke
Total small vessel disease score and risk of recurrent stroke
Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke
Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality